268 related articles for article (PubMed ID: 27856806)
1. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
[TBL] [Abstract][Full Text] [Related]
2. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
4. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
6. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
7. Is there a new dawn for selective mineralocorticoid receptor antagonism?
Luther JM
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis.
Shah SS; Zhang J; Gwini SM; Young MJ; Fuller PJ; Yang J
J Hum Hypertens; 2024 May; 38(5):383-392. PubMed ID: 38200100
[TBL] [Abstract][Full Text] [Related]
9. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
Currie G; Taylor AH; Fujita T; Ohtsu H; Lindhardt M; Rossing P; Boesby L; Edwards NC; Ferro CJ; Townend JN; van den Meiracker AH; Saklayen MG; Oveisi S; Jardine AG; Delles C; Preiss DJ; Mark PB
BMC Nephrol; 2016 Sep; 17(1):127. PubMed ID: 27609359
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B; MacDonald TM; Morant S; Webb DJ; Sever P; McInnes G; Ford I; Cruickshank JK; Caulfield MJ; Salsbury J; Mackenzie I; Padmanabhan S; Brown MJ;
Lancet; 2015 Nov; 386(10008):2059-2068. PubMed ID: 26414968
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
13. The comparative effectiveness of fourth-line drugs in resistant hypertension: An application in electronic health record data.
Sinnott SJ; Smeeth L; Williamson E; Perel P; Nitsch D; Tomlinson LA; Douglas IJ
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1267-1277. PubMed ID: 31313390
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
15. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.
Bazoukis G; Thomopoulos C; Tsioufis C
J Hypertens; 2018 May; 36(5):987-994. PubMed ID: 29356711
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
18. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
Bobrie G; Frank M; Azizi M; Peyrard S; Boutouyrie P; Chatellier G; Laurent S; Menard J; Plouin PF
J Hypertens; 2012 Aug; 30(8):1656-64. PubMed ID: 22728905
[TBL] [Abstract][Full Text] [Related]
19. [The revived interest in aldosterone antagonists].
Waeber B
Rev Med Suisse; 2006 Sep; 2(78):2055-8. PubMed ID: 17019841
[TBL] [Abstract][Full Text] [Related]
20. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
